<DOC>
	<DOCNO>NCT01302041</DOCNO>
	<brief_summary>To evaluate effect enzalutamide prostate specific antigen ( PSA ) level men prostate cancer .</brief_summary>
	<brief_title>A Study Test Enzalutamide Effective Safe Prostate Cancer Patients Who Have Never Had Hormone Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Histologically confirm prostate cancer ( stage ) androgen deprivation therapy indicate ( except indicate neoadjuvant/adjuvant therapy ) Asymptomatic prostate cancer Noncastrate level testosterone ( ≥ 8 nmol/L ( 230 ng/dL ) ) screen PSA ≥ 2 ng/mL screening Has previously currently receive : Hormonal therapy intent treat prostate cancer Systemic glucocorticoid Chemotherapy intent treat prostate cancer Opiate analgesic pain prostate cancer Radiation therapy treatment primary tumor metastasis Has history know suspected brain skull metastases leptomeningeal disease Has history seizure include febrile seizure condition may predispose seizure history loss consciousness transient ischemic attack Clinically significant cardiovascular disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>bone turnover</keyword>
	<keyword>hormone-naïve</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>